Impact of Diabetes on Transdermal Fentanyl Titration
Author Information
Author(s): Mizuno Satoshi, Takabayashi Makiko, Makihara Hiroko, Ogai Kazuhiro, Tsukui Kei, Ito Yuriko, Kawakami Takahiro, Hara Yusuke, Fujita Arimi, Tokudome Yoshihiro, Akase Tomoko, Kato Yukio, Shimada Tsutomu
Primary Institution: Kanazawa University
Hypothesis
Skin changes due to diabetes mellitus (DM) would affect the titration period of transdermal fentanyl.
Conclusion
Transdermally administered fentanyl reaches the steady state earlier in cancer patients with diabetes.
Supporting Evidence
- The titration period for transdermal fentanyl ranged from 5 to 39 days.
- Patients with unspecified diabetes had a significantly shorter titration period.
- Ceramide content in the skin was decreased by approximately 30% in diabetic rats.
- The absorption rate constant of fentanyl was increased by approximately 1.4-fold in diabetic rats.
Takeaway
If you have diabetes and need pain relief from fentanyl patches, you might feel better faster than someone without diabetes.
Methodology
The study included a retrospective analysis of cancer patients on transdermal fentanyl and a diabetic animal model study using GK rats.
Potential Biases
Potential biases include the absence of plasma fentanyl concentration data and unknown effects of cancer chemotherapy on skin.
Limitations
The study had limitations including a lack of validation for titration period criteria and a single-center patient entry.
Participant Demographics
The study analyzed 387 cancer patients, with a majority having comorbidities including diabetes.
Statistical Information
P-Value
0.021
Confidence Interval
0.217–0.884
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website